Who and when should we screen for prostate cancer? Interviews with key opinion leaders.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 26612204.
- Also identified by DOI 10.1186/s12916-015-0526-x and PMC identifier PMC4530615.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Prostate cancer screening using prostate-specific antigen (PSA) is highly controversial. In this Q & A, Guest Editors for BMC Medicine's 'Spotlight on Prostate Cancer' article collection, Sigrid Carlsson and Andrew Vickers, invite some of the world's key opinion leaders to discuss who, and when, to screen for prostate cancer. In response to the points of view from the invited experts, the Guest Editors summarize the experts' views and give their own personal opinions on PSA screening.